Pilot Study of Fixed-Infusion Rate Gemcitabine with Cisplatinand Dexamethasone in Patients with Relapsed or Refractory Lymphoma
- 1 June 2004
- journal article
- clinical trial
- Published by Elsevier in Clinical Lymphoma
- Vol. 5 (1) , 45-49
- https://doi.org/10.3816/clm.2004.n.009
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Gemcitabine as a single agent in the treatment of relapsed or refractory low‐grade non‐Hodgkin's lymphomaBritish Journal of Haematology, 2001
- Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemiaLeukemia Research, 2001
- Treatment of refractory T‐cell malignancies using gemcitabineBritish Journal of Haematology, 2001
- Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 PatientsJournal of Clinical Oncology, 2000
- Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II StudyJournal of Clinical Oncology, 2000
- Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999
- New drugs in the treatment of Hodgkin’s diseaseAnnals of Oncology, 1998
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989